Form 4: Protara Therapeutics Director Roger Garceau Acquires Stock Options

Director Roger Garceau acquired stock options for 10,000 shares of Protara Therapeutics, Inc. at an exercise price of $2.67 on June 7, 2024.

Summary

• On June 7, 2024, Roger Garceau, a director of Protara Therapeutics, Inc., acquired stock options for 10,000 shares.
• The exercise price of these options is $2.67.
• The options vest in equal monthly installments over 12 months, with full vesting by the next annual stockholder meeting or upon a change of control, contingent on continuous service on the Board.
• The expiration date for these options is June 6, 2034.
• Following the transaction, Garceau directly owns derivative securities for 10,000 shares.

Sentiment

Score: 5

Explanation: This is a neutral event, simply a disclosure of stock option grants to a director, which is a common practice.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the actions of company directors. It is a standard practice in publicly traded companies.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders, primarily providing transparency to shareholders regarding director compensation.

Key Dates